These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 19799082)
1. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer]. Wang YJ; Wang N; Wang B; Qin WX; Xue CY Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082 [TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy]. Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696 [TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer]. Zhang P; Xu BH; Ma F; Li Q Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):128-31. PubMed ID: 20403244 [TBL] [Abstract][Full Text] [Related]
4. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression]. Fan Y; Guan Y; Zhao WH; Li Q; Xu BH Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993 [TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancers: unique clinical presentations and outcomes. Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062 [TBL] [Abstract][Full Text] [Related]
6. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients]. Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471 [TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes]. Zhang HM; Zhang BN; Xuan LX; Zhao P Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556 [TBL] [Abstract][Full Text] [Related]
8. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040 [TBL] [Abstract][Full Text] [Related]
9. Clinical and biological characteristics of breast cancer. Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A J BUON; 2010; 15(4):660-7. PubMed ID: 21229626 [TBL] [Abstract][Full Text] [Related]
10. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors. Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944 [TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion]. Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853 [TBL] [Abstract][Full Text] [Related]
13. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes. Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K J BUON; 2013; 18(3):608-13. PubMed ID: 24065471 [TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics and prognosis of different subtypes of breast cancer]. Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression. Demir H; Turna H; Can G; Ilvan S J BUON; 2010; 15(4):774-82. PubMed ID: 21229645 [TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival. Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N Oncology; 2013; 84(3):135-40. PubMed ID: 23235554 [TBL] [Abstract][Full Text] [Related]
17. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I J BUON; 2012; 17(2):277-83. PubMed ID: 22740206 [TBL] [Abstract][Full Text] [Related]
18. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both? Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391 [TBL] [Abstract][Full Text] [Related]
19. [Clinical features and prognosis analysis of different breast cancer molecular subtypes]. Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463 [TBL] [Abstract][Full Text] [Related]
20. [Efficacy of modified radical operation of preserving nipple-areolar complex on early stage breast cancer]. Wang SY; Zhu ZZ; Peng DF; Zhang RX; Dong HM; Yao TJ; Zhang H Ai Zheng; 2009 Apr; 28(4):408-11. PubMed ID: 19622302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]